Prescription opioids continue to be the most frequently misused prescription drugs in the United States, having caused nearly 300,000 deaths over the past two decades. Signed into law in 2022, the No Pain Act expands Medicare reimbursement for specific non-opioid pain management options. Carolyn Liptak, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence, and Dr. Phil Mentler, Senior Consulting Director at Vizient join Program Host Stacy Lauderdale to discuss the implications of the No Pain Act, which took effect on January 1, 2025.   Guest speakers:  Carolyn Liptak, MBA, RPh Pharmacy Executive Director Vizient   Phillipe Mentler, Pharm.D, BCPS Senior Consulting Director Vizient   Host:  Stacy Lauderdale, Pharm.D, BCPS Associate Vice President Vizient    Show Notes:  [01:49-03:48] Background on the No Pain Act [03:49-05:03] What is new as of January 1, 2025 [05:04-05:37] The difference between a hospital outpatient department versus an ambulatory surgical center [05:38-06:30] Other drugs and or devices that are on the list other than Exparel [06:31-07:42] What specifically prevents multi modal drugs and therapy from being added to the list [07:43-08:24] Specific language that needs to be included in the FDA labeling for non-opioids to be considered for reimbursement under the Act [08:25-10:50] Reimbursement basics of the NO PAIN Act [14:32-15:44] Reimbursement [15:45-17:04] The importance of opioids in pain management   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed